FindTrial
Sign In

Clinical evaluation of autoantibody 7-AAb panel for its diagnostic and prognostic value in hepatocellular carcinoma

Clinical evaluation of autoantibody 7-AAb panel for its diagnostic and prognostic value in hepatocellular carcinoma

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036244
Enrollment
Unknown
Registered
2020-08-22
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Gold Standard:1.Diagnosis of hepatocellular carcinoma by CT or MRI
2.Pahtological diagnosis of hepatocellular carcinoma.
Index test:Autoantibody&#32
against&#32
CIAPIN1,&#32
EGFR,&#32
MAS1,&#32
SLC44A3,&#32
ASAH1,&#32
UBL7&#32
and&#32
ZNF428

Sponsors

Zhongshan Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients enrolled in Liver Surgery Department, aged between 18 to 70, male or female. Patients enrolled in Physical Examination Department, aged between 18 to 70, male or female.

Exclusion criteria

Exclusion criteria: Patients with autoimmune diseases or servere health problems which may have significant impact on survival period.

Design outcomes

Primary

MeasureTime frame
7???????;SEN, SPE, ACC, AUC of ROC;—

Countries

China

Contacts

Public ContactShu Zhang

Zhongshan Hospital of Fudan University

zhang.shu@zs-hospital.sh.cn+86 13764966023

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026